

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

T. Myers et al.

Serial No.: 09/886,271

Filed: 22 June 2001

For: Non-Genetic Based Protein Disease
Marker

Examiner: TBA

Group Art Unit: TBA

INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.97 and § 1.98, Applicants bring the disclosure attached and listed on completed Form PTO-1449 to the attention of the Examiner and request that the reference be considered and made of record in the instant application.

Since the instant Information Disclosure Statement is being filed prior to issuance of a first Office Action on the merits, no certification under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(b) is required.

Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the instant application.

Prompt examination on the merits is respectfully requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Dean H. Nakamura".

Dean H. Nakamura
Reg. No. 33,981Roylance, Abrams, Berdo & Goodman, L.L.P.
1300 19th Street, N.W., Suite 600
Washington, D.C. 20036
(202) 659-9076

Dated: 18 September 2001

BEST AVAILABLE COPY

